compound semaglutide results Weight Loss Injections in Lexington, SC 1 Year On A GLP1

In the STEP 1 semaglutide trial (Wilding et al., NEJM , 2021) and the SURMOUNT-1 tirzepatide trial (Jastreboff et al., NEJM , 2022), nausea affected roughly 44% of semaglutide patients and about 24% of tirzepatide patients at the maximum dose

References Bozkurt B, Ahmad T, Alexander K, et al

This was the first Human evidence suggesting disease-modifying potential of incretin-based therapies in neurodegeneration

Mills, C

However, mounting evidence points to their potential benefits in dermatologic conditions, including HS and psoriasis, particularly in patients with metabolic comorbidities

These findings underscore the importance of identifying dosedependent and circuitspecific mechanisms in humans, as differential engagement of stressrelated versus rewardrelated neural pathways may help explain the heterogeneous anxietyrelated outcomes observed in clinical settings